Aripiprazole possibly worsens psychosis

Sriram Ramaswamy, Dewan Vijay, Marcil William, S. Pirzada Sattar, Fernandes Praveen, Frederick Petty

Research output: Contribution to journalArticlepeer-review

67 Scopus citations


Aripirazole is a novel antipsychotic that functions as a partial agonist at the dopamine D2 receptor and, thus, might theoretically worsen psychosis. We report a series of four clinical cases of exacerbation of psychosis related to initiation of aripiprazole therapy. Cases 1 and 2 demonstrated the worsening of psychosis following initiation of aripiprazole (15-30 mg daily) while tapering off the previous atypical antipsychotic. Cases 3 and 4 demonstrated worsening of psychosis following the addition of aripiprazole (15-30 mg daily) to an atypical antipsychotic. In two out of the four cases, discontinuation of arpiprazole resulted In improvement of psychotic symptoms. Although the cases presented are suggestive of a relationship between initiation of aripiprazole therapy and worsening of psychosis, further research is needed to clarify any potential association.

Original languageEnglish (US)
Pages (from-to)45-48
Number of pages4
JournalInternational Clinical Psychopharmacology
Issue number1
StatePublished - Jan 1 2004

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Aripiprazole possibly worsens psychosis'. Together they form a unique fingerprint.

Cite this